Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Genus reports mixed full year, warns of currency headwinds
(Sharecast News) - Genus reported strategic progress amid challenging market conditions, particularly in China, in its preliminary full-year results on Thursday, although it warned of potential currency headwinds going forward. The FTSE 250 animal genetics company reported a mixed financial performance, with structural changes contributing to stronger results in the second half of the year ended 30 June.
In the latter half of the year, Genus recorded an adjusted operating profit, including joint ventures, of £40m - a 15% year-on-year increase in constant currency.
That was aided by £9.4m in management actions.
In contrast, the first half saw a 17% decline, bringing the full-year adjusted operating profit, including joint ventures, to 3% lower in constant currency and 9% lower in actual currency.
Adjusted profit before tax fell 8% in constant currency to £59.8m, while statutory profit before tax plunged 86% to £5.5m, due to a reduction in the value of biological assets and exceptional expenses of £24.6m.
Genus introduced a new cash conversion metric, achieving 71%, up from 53% in 2023.
Net debt increased to £248.7m, maintaining a ratio of 2.0x adjusted EBITDA.
Genus said it made significant strategic progress, after the ABS division implemented its value acceleration programme (VAP), which improved margins and cash generation, delivering a £7.3m profit benefit in 2024, with more savings expected in 2025.
The company also completed a review of its research and development, focusing on key work streams and achieving £2.4m in savings this year.
Notably, Genus made progress on its PRRS-resistant pig (PRP) programme, with favourable regulatory decisions in Brazil and Colombia and ongoing discussions with the US FDA, which was expected to approve the product by 2025.
The company also submitted applications to Canadian and Japanese regulators.
Divisional performance varied, as PIC saw resilient growth outside China, with royalty revenue increasing by 4% in constant currency.
However, PIC China's operating profit dropped 60% due to market difficulties and supply chain investments.
Meanwhile, ABS faced challenges, particularly in China, but the VAP programme helped mitigate profit declines.
Looking ahead, Genus said it expected stable or improving market conditions, with solid profit growth from PIC and a recovery in ABS profits in 2025.
However, the company remained cautious about China's market and anticipated currency headwinds of £8m to £9m if current exchange rates persisted throughout the next financial year.
"Genus made significant progress against its strategic priorities during the 2024 financial year," said chief executive officer Jorgen Kokke.
"I am confident that our decisive actions to structurally strengthen the group will yield significant benefits in the years to come."
Kokke said that in the 2025 period, the company would continue to execute against its strategic priorities, adding that it expected to achieve "significant growth" in group adjusted profit before tax in constant currency, in line with market expectations.
"However, sterling has continued to appreciate against key foreign currencies since our trading update on 17 July, and we now expect a currency headwind of approximately £8m to £9m in 2025, if current exchange rates continue throughout the fiscal year."
At 1011 BST, shares in Genus were down 3.24% at 1,735.95p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.